Nanologica Publishes Prospectus in Connection with the Listing on Nasdaq Stockholm

On 11 March 2022, Nanologica AB (publ) announced that Nasdaq Stockholm’s Listing Committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market, conditioned upon customary conditions being fulfilled. The prospectus prepared in connection with the listing has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Nanologica’s website and will be made available on the Swedish Financial Supervisory Authority’s website

Link to prospectus (only available in Swedish):

The first day of trading on Nasdaq Stockholm’s main market is scheduled for Tuesday 29 March 2022 and the last day of trading on Spotlight Stock Market is scheduled for Monday 28 March 2022. The shares will be traded under the same ticker (NICA) and ISIN-code (SE0005454873). There is no offering or issue of new shares in connection with the list change, and shareholders in Nanologica do not need to take any actions.

Advokatfirman Lindahl has acted as legal advisor in connection with the listing on Nasdaq Stockholm.


For further information, please contact:

Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail:


About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases.  In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company’s share (NICA) is listed on Spotlight Stock Market. For further information, please visit